Shared on07 May 25Fair value Increased 2.17%
AnalystLowTarget has increased revenue growth from -1.1% to 0.7%.
Loading...
Patent Expirations And Biosimilar Pressures Will Diminish Value
AnalystLowTarget's Fair Value
US$320.81
37.2% overvalued intrinsic discount10 Sep
US$440.00
1Y
22.8%7D
-2.9%1Y
22.8%7D
-2.9%You can edit this narrative until May 12 6:03 AM. Then, changes will post as Updates.